Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov page’s displayed site revision changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe clinical trial record for the long-term efgartigimod study is displayed, including its eligibility criteria, study design and outcomes, and participating locations. The prior access-denied error is no longer shown.SummaryDifference83%

- Check21 days agoChange DetectedThe study page now displays a 403 Forbidden message with a Home link. The site revision changed from v3.7.2 to v3.8.0.SummaryDifference0.6%

- Check28 days agoChange DetectedA site-wide NIH notice about using “Super Intelligence” in place of “Artificial Intelligence” appears above the unchanged 403 error page.SummaryDifference1%

- Check35 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 Forbidden page.SummaryDifference0.2%

- Check42 days agoChange DetectedThe ClinicalTrials.gov page footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.